Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Oct 23;12(5):821–827. doi: 10.1016/j.cgh.2013.10.011

Table 2.

Plasma 25(OH)D and risk of all malignancy in patients with inflammatory bowel diseases

Vitamin D stratum No cancer
[N(%)]
Cancer
[N(%)]
Unadjusted OR (95% CI) Adjusted OR (95% CI)
≥ 30 ng/mL 1,065 (95%) 52 (5%) 1.0 1.0
20 – 29.9 ng/mL 741 (92%) 66 (8%) 1.82 (1.25 – 2.66) 1.69 (1.15 – 2.51)
< 20 ng/mL 793 (90%) 92 (10%) 2.38 (1.67 – 3.38) 1.82 (1.25 – 2.65)

OR – odds ratio, CI – confidence interval

Adjusted for age, gender, race, season of measurement, duration of follow up, immunosuppression use, and IBD type